- Home
- ALNY
as 02-21-2025 4:00pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 35.0B | IPO Year: | 2004 |
| Target Price: | $305.86 | AVG Volume (30 days): | 669.1K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $141.98 - $304.39 | Next Earning Date: | 02-13-2025 |
| Revenue: | $2,248,243,000 | Revenue Growth: | 22.97% |
| Revenue Growth (this year): | 22.5% | Revenue Growth (next year): | 30.54% |
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Feb 13 '25 | Sell | $257.20 | 2,103 | $531,447.79 | 14,839 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Feb 13 '25 | Sell | $258.13 | 1,213 | $309,526.58 | 81,551 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Feb 13 '25 | Sell | $258.13 | 967 | $246,749.79 | 32,860 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jan 27 '25 | Sell | $285.00 | 52,592 | $14,988,720.00 | 11,989 | |
| SHARP PHILLIP A | ALNY | Director | Jan 23 '25 | Sell | $275.00 | 11,250 | $3,093,750.00 | 0 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Dec 12 '24 | Sell | $251.62 | 1,752 | $439,759.94 | 11,989 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Nov 25 '24 | Sell | $251.34 | 3,000 | $754,946.54 | 14,839 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Nov 25 '24 | Sell | $250.35 | 5,219 | $1,309,852.75 | 81,551 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Nov 25 '24 | Sell | $250.35 | 1,682 | $422,144.31 | 11,989 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Nov 25 '24 | Sell | $250.35 | 1,469 | $368,685.86 | 13,191 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $787,904, According to a Recent SEC Filing
MT Newswires
4 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $531,448, According to a Recent SEC Filing
MT Newswires
4 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $309,527, According to a Recent SEC Filing
Zacks
4 days ago
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Morningstar Research
8 days ago
Analyst Report: Alnylam Pharmaceuticals, Inc.
Zacks
8 days ago
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
MT Newswires
8 days ago
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating
Simply Wall St.
8 days ago
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
Compare ALNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.